Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.95 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What are ACAD's key financials?
ACAD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ACAD recently traded at $20.95. Market cap is $3.54B. P/E ratio is 9.34. Revenue is $1.10B.
ACAD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ACAD recently traded at $20.95. Market cap is $3.54B. P/E ratio is 9.34. Revenue is $1.10B.
Is ACAD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.
